New Drug for Breast Cancer with Specific Genetic Mutations

Alpelisib (Piqray) is now approved to treat postmenopausal women or men who have hormone receptor–positive, human epidermal growth factor receptor 2–negative, PIK3CA-mutated, advanced or metastatic breast cancer that has progressed during or after endocrine-based therapy.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research